1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Drug Toxicity: new trials by email Literature Review of Drug Toxicity trials Research Report on Drug Toxicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis Infliximab, Methylprednisolone, Prednisone - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | Massachusetts General Hospital | 42 | 2020-08-31 | 2026-10-29 |
Colitis (1) · Drug-Related Side Effects and Adverse Reactions (1) · Melanoma (1) · Skin Neoplasms (1)
Chemically-Induced Disorders (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Intestinal Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1)
Infliximab (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Prednisone (1)
Massachusetts General Hospital (1)
United States (1)